4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Systemic Lupus Erythematosus by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1196 ongoing clinical trials involving Systemic Lupus Erythematosus
Of the 1196 trials,473 trials are in Phase III
Furthermore, 418 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Systemic Lupus Erythematosus by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Systemic Lupus Erythematosus, an Immunology condition. The largest number of ongoing clinical trials for Systemic Lupus Erythematosus is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Systemic Lupus Erythematosus-related drug trials.

GlaxoSmithKline Plc: The leading ongoing Systemic Lupus Erythematosus related clinical trial sponsor

GlaxoSmithKline Plc is the top sponsor for Systemic Lupus Erythematosus-related ongoing clinical trials.

Bristol-Myers Squibb Co, Novartis AG, F. Hoffmann-La Roche Ltd, Renji Hospital, and AstraZeneca Plc are among other notable clinical trial sponsors involved in Systemic Lupus Erythematosus. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Systemic Lupus Erythematosus

Tacrolimus (Modigraf, Prograf, Prograft), Belimumab (Benlysta) and Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) are key marketed drugs involving Systemic Lupus Erythematosus.

Tacrolimus (Modigraf, Prograf, Prograft) is an immunosuppressive agent. It functions via the Calcineurin Inhibitor mechanism of action. Prograf is formulated as hard gelatin capsules, granules, powder for suspension for oral route of administration, and injectable solution for the intravenous and intravascular route of administration. Prograf is used to treat prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants used concomitantly with adrenal corticosteroids, interstitial pneumonia associated with polymyositis/ dermatomyositis. Tacrolimus was first approved in 1993 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Astellas Pharma US Inc.

Belimumab (Benlysta) is a human IgG1 monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BlyS), which acts as an immunosuppressant agent. It functions via Tumor Necrosis Factor Ligand Superfamily Member 13B Inhibitor mechanism of action. It is formulated as Lyophilized powder for solution and solution for the intravenous and subcutaneous route of administration. Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g positive anti-dsDNA and low complement) despite standard therapy, and for the treatment of systemic lupus erythematosus inadequately treated with existing treatments in pediatrics. Belimumab was first approved in 2011 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by GlaxoSmithKline LLC